Back to News
Market Impact: 0.3
Artelo Reports ART27.13 Matches Semaglutide Weight Loss In Obesity Model
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Artelo Biosciences reported new nonclinical data for ART27.13 showing weight loss comparable to semaglutide in an obesity model. The company also indicated greater weight loss under additional, unspecified conditions in the truncated report, providing early supportive evidence for its clinical-stage obesity therapy program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ARTL0.72
More News
- Companies promised AI gains— here's how the payoff showed up in earnings
- FBI blames North Korea for record $6.3bn crypto heist
- Binance to resume crypto withdrawals in phases after record $6 billion hack
- AWS grows 39% and Amazon will spend even more on AI in 2027
- SpaceX loses bid to toss NAACP lawsuit over Memphis data center air pollution
- U.S workers just took home their smallest share of capital since at least 1947—and the lowest ever recorded